| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner
4 companies
Invest A/s Lundbeckfond last filed a Form 4 in November 2023, as Director, 10% Owner at IOBT. The filings on record cover 4 companies. Invest A/s Lundbeckfond's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,432,722 shares of ELVN. Net of sales, the ELVN filings show accumulation of 187,500 shares.
Invest A/s Lundbeckfond has 5 Form 4 filings on record from May 2019 to November 2023, across 4 companies: 10% Owner at Lexeo Therapeutics (LXEO), 2023; Director, 10% Owner at IO Biotech (IOBT), 2021–2023; 10% Owner at Enliven Therapeutics (ELVN), 2020, and 1 more.
The 12 reported transactions were 6 conversions, 4 open-market purchases, 1 stock award and 1 option or other derivative award.
Counted by filing, the open-market trades come to 4 purchases worth about $39.2M and no sales.
The largest open-market purchase was 2,142,857 shares of IOBT at an average $14.00 on November 9, 2021, about $30.0M. Twelve months later IOBT was down 81%.
Shares as reported in the last Form 4 for each company; the most recent is from November 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7, 2023 | LXEO Lexeo Therapeutics, Inc. | 10% Owner | Buy | 227,272 | $11.00 | $2,499,992.00 | +14.1% | +61.6% | -21.6% | |
| Nov 9, 2021 | IOBT Io Biotech, Inc. | 10% Owner | Buy | 2,142,857 | $14.00 | $29,999,998.00 | +54.9% | -36.9% | -81.2% | |
| Mar 16, 2020 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Buy | 187,500 | $16.00 | $3,000,000.00 | +15.1% | - | - | |
| May 9, 2019 | TRVI Trevi Therapeutics, Inc. | 10% Owner | Buy | 375,000 | $10.00 | $3,750,000.00 | +48.3% | - | - |